SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
TargeGen, Inc. Initiates Multi-Center Phase II Clinical Trial Of TG100801, a Topically Applied Kinase Inhibitor In Macular Degeneration Patients